| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
4 companies
Lundbeckfond Invest A/s is a Director, 10% Owner at IO Biotech, Inc. with holdings across 4 companies. Recent SEC Form 4 filings include 4 buys and 0 sells.
Estimated insider holdings value: $86.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7, 2023 | LXEO Lexeo Therapeutics, Inc. | 10% Owner | Buy | 227,272 | $11.00 | $2,499,992.00 | +14.1% | +61.6% | -21.6% | |
| Nov 9, 2021 | IOBT Io Biotech, Inc. | 10% Owner | Buy | 2,142,857 | $14.00 | $29,999,998.00 | +54.9% | -36.9% | -81.2% | |
| Mar 16, 2020 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +15.1% | - | - | |
| May 9, 2019 | TRVI Trevi Therapeutics, Inc. | 10% Owner | Buy | 375,000 | $10.00 | $3,750,000.00 | +48.3% | - | - |